Lenalidomide cliff deeper than offset; guidance trajectory tight
Reported PAT down 57% YoY, but Adcock's abnormal flu-season earnings mask the true weakness. Normalized profit is half the headline; FY27 guidance requires 20% ramp to deliver.
₹206.5 Cr
−57% YoY
₹84.3 Cr
40% of total; abnormal flu bump
₹35–40 Cr/qtr
normalized run-rate (at 35.75% stake)
~₹160 Cr
ex abnormal Adcock impact
The headline screams alarm — 57% PAT collapse — but the story beneath is worse. ₹84.3 crore (40% of reported profit) came from Adcock's South African flu season. Strip that out and NATCO's core earnings this quarter were roughly half the printed number. The real tension: management maintained FY27 guidance (₹700–750 Cr PAT; ₹3,400–3,500 Cr revenue) despite Q1 annualizing to just ₹2,940 crore — a shortfall of nearly ₹500 crores that would require sustained 20%+ growth in the next three quarters to recover.
Where the profit came from
Adcock Ingram contributed ₹84.3 crore of the ₹206.5 crore reported PAT. This is not normal. NATCO's 35.75% stake in the South African pharma distributor (note: increased to 49% post-quarter in July) typically yields ₹35–40 crore per quarter. The flu season bump was acknowledged on the call as 'abnormal' and 'not repeatable' — a frank admission that without the seasonal tailwind, consolidated PAT this quarter would have landed around ₹160 crore (still down 41% YoY from ₹271 crore in Q1 FY26). If Adcock normalizes to its baseline, the next quarter's PAT could swing sharply lower, creating downside risk to the full-year guidance.
The Lenalidomide cliff is structural, not temporary
Revenue fell 45% YoY to ₹735.2 crore, a collapse driven entirely by Lenalidomide (Revlimid), which management now describes as 'negligible' — a candid admission that this pillar of historical earnings is gone for good. Revlimid was the reason NATCO could deliver ₹1,390+ crore in Q1 FY26; it is not coming back. Management adjusted expectations downward by acknowledging this structural loss rather than chasing recovery. The company is not guiding a Lenalidomide recovery; instead it is betting the spread on: (1) domestic base business (₹130 crore, up 21.5% QoQ), (2) Brazil oncology (₹178 crore, up 180% YoY), and (3) future pipeline launches (carfilzomib, olaparib). Whether these three can collectively close a ₹600+ crore annualized revenue gap is the bear case.
Base business double-digit growth offsets Lenalidomide decline
Domestic base 107→130 Cr (+21.5% QoQ); semaglutide contributor. International formulations 477 Cr (seasonal decline despite Brazil 180% growth).
Supported, but offset is partial, not full
Brazil momentum is structural and material (180% growth)
Brazil ₹178 Cr, confirmed 180% YoY, oncology-pipeline-driven. Positive. But ₹178 Cr annualized (~₹710 Cr for year) is still <30% of Lenalidomide's loss.
Supported; growth is real but magnitude gap remains
EBITDA margin improved QoQ at 30.9%
EBITDA ₹245.7 Cr, margin 30.9%. Improvement on international and domestic performance, lower operating costs.
Supported
Adcock flu season abnormal and non-repeatable; normalized to ₹35–40 Cr/quarter
CFO confirmed baseline ₹35–40 Cr/quarter at prior 35.75% stake. Implies ₹49–56 Cr normalized baseline at new 49% stake (post-July).
Supported with recalculation needed for 49% stake
What changed on this call
Three structural shifts emerged: 1. Adcock stake increased to 49%. In July 2026, NATCO invested ₹1,060 crore to lift its stake from 35.75% to 49%. This deepens South Africa conviction and signals long-term commitment, but it amplifies Adcock earnings volatility. This quarter's ₹84.3 crore Adcock contribution was 40% of consolidated PAT; volatility at that scale matters more. Synergies (NATCO products via Adcock distribution in South Africa) are targeted for '28+, but near-term, the increased stake amplifies earnings noise. 2. Semaglutide in India is a profitability dead-end near-term. The drug generates ~₹2 crore/month from NATCO's branded product, but the market is 'cutthroat' and pricing pressure is 'intense'. Management was blunt: 'doesn't lose money, but doesn't make much money either.' The India GLP-1 wave is not a NATCO story. 3. Carfilzomib launch timing is confidential, but on track for CY27. Plant upgrade is underway (due year-end). Launch date is opaque, but the product is binary upside for international oncology revenue. Exact timing (Q1 vs Q4 CY27) and pricing power are unknowns.
Brazil oncology 180% growth to ₹178 Cr; multiple launches planned '27
Domestic base business +21.5% QoQ to ₹130 Cr; sustainable momentum
Adcock synergies (NATCO products in South Africa) targeted '28+
eGenesis pig kidney transplant progressing (2 patients >8 months); biotech upside
EBITDA margin held at 30.9%; operating leverage in place
Reported PAT inflated 22% by Adcock flu season; normalized earnings ~₹160 Cr
Q1 revenue annualizes to ₹2,941 Cr; 11% below FY27 target (₹3,400 Cr)
Guidance maintained, not raised, despite 'confidence' claims
Semaglutide stuck in breakeven; India GLP-1 market 'cutthroat'
Olaparib litigation binary; CEO couldn't recall trial date (governance red flag)
Crop Health EBITDA loss Q1; demerger delayed to March
Adcock normalization risk: ₹45–50 Cr earnings swing Q2 if flu boost fades
Revenue cliff risk — Lenalidomide structural loss unmatched by Brazil/base ramp
HighQ1 annualized ₹2,941 Cr vs. ₹3,400+ target leaves ₹459–559 Cr gap. Requires 16%+ ramp in Q2–Q4. If that doesn't happen, full-year misses and guidance credibility sinks.
Adcock earnings normalization cliff and consolidated PAT volatility
High₹84.3 Cr this quarter vs. ₹35–40 Cr baseline = ₹45–50 Cr earnings drop next quarter. At 35% of consolidated PAT swing, if management doesn't bridge elsewhere, Q2 could look like a 30% miss.
Pipeline execution binary (carfilzomib, olaparib) with limited visibility
HighCarfilzomib launch date is confidential; olaparib trial date unknown (CEO couldn't recall). FTF targets ambitious (1–2 this year out of 2–3/year). Launch delays kill '27 and '28 growth narrative.
Semaglutide India market saturation and margin compression
MediumBrand does ₹2 Cr/month; market cutthroat; no path to meaningful profit near-term. Repeated management warnings on pricing suggest competition is structural, not cyclical.
Crop Health unprofitable; demerger timeline slipping
MediumQ1 EBITDA loss (₹40 Cr revenue). Demerger delayed 2–3 months. If Q2 doesn't deliver 'significantly better' and FY27 breakeven misses, consolidated ROE takes another hit.
How the street is reading it
Day-1 price action post-result
−1.48% decline (46.1% delivery volume)
Sellers won the first day. The 46% delivery suggests institutional participation in the exit. Soft initial reaction is typical on guidance miss stories; the market did not embrace the print.
Price vs. moving averages
₹889.8 vs. SMA20 ₹922, SMA50 ₹918, SMA200 ₹942 (below all three)
Stock is trading below all major moving averages. Downtrend is intact. RSI 40.2 (neutral, not yet oversold). Technicals show weakness, not panic-driven selling.
Drawdown from all-time high
₹1,226.8 (ATH) → ₹889.8 now = −27.47% decline
Material drawdown, but 52w low is ₹792 (stock 12% above that). Suggests weakness is recognized but not panic-capitulation. Room to fall if guidance misses.
FII/DII flows (Q1 FY27 vs. Q4 FY26)
FII −0.38pp (17.37%→16.99%); DII +0.16pp (5.46%→5.62%)
FIIs are net trimming; DII flat. International money is backing away, signaling skepticism on guidance recovery narrative. Domestic buying is not offsetting foreign exit.
Volume trend
INCREASING
Higher volume on the decline is bearish (conviction selling, not panic). Suggests informed institutional exit, not retail fear.
The market's verdict is clear: skepticism on management's ability to recover to FY27 targets. The day-1 -1.48% decline, FII trimming, and below-MA trading all suggest the street is not convinced Brazil + base business can offset Lenalidomide + Adcock normalization. The stock is 27% below its all-time high, below all moving averages, and seeing institutional exits. This is not capitulation (which would show at new lows), but it is a broken uptrend.
1 · Q2 FY27 revenue run-rate and sequential bridge
Management needs ₹850+ Cr/quarter average to hit the ₹3,400 Cr FY27 floor. Q1 was ₹735 Cr. Q2 is the first read on whether the ramp is real or guidance is at risk. Watch the Adcock contribution level carefully; if it drops to baseline (₹35–40 Cr normalized at 35.75% stake), consolidated PAT will swing sharply Q2 vs. Q1.
2 · Carfilzomib launch confirmation and early uptake
Confidential launch date is CY27 (this year). Plant upgrade due year-end. Once a date is announced, watch for early order commentary, pricing power, and competitive positioning. This is a binary catalyst for '27–'28 earnings.
3 · Olaparib patent litigation outcome and trial progress
Trial scheduled 'next few months'. Binary outcome: win = major exclusivity asset; lose = product at risk. CEO's inability to recall trial date on the call is a governance concern. Watch for management updates on trial progress and timeline clarity.
4 · Crop Health Q2 performance and FY27 breakeven trajectory
Management expects Q2 to be 'significantly better' (strongest agro quarter). If Q2 is still loss-making or marginal, FY27 breakeven goal is at risk. Also monitor demerger progress (now targeted March 2027, delayed 2–3 months).
NATCO is not a step-change story; it is a reset quarter in a long reset. Lenalidomide is gone, and the company is rewriting its earnings model around Brazil, domestic base, pipeline, and Adcock. None of that is false — Brazil is real, Adcock is strategic, the pipeline has merit. But the gap between Q1's ₹735 crore run rate and FY27's ₹3,400+ crore target is too large to bridge with confidence. Management's decision to maintain (not raise) guidance suggests even the company's internal compass is not pointed at the upper end.
The number to track from here is Q2 revenue. If it comes in below ₹800 crore, FY27 guidance is probably at risk. If it comes in above ₹850 crore, the ramp narrative gains traction. The next two quarters will determine whether this is a cyclical reset or a structural margin erosion story. Hold for now; the debate is unresolved.
Natco Q1 FY27: consolidated PAT falls 57% YoY to ₹206.5 Cr on Lenalidomide exit
PAT -57.01% YoY · revenue -44.68% · margins compressing
₹735.2 Cr
-44.68% YoY
₹206.5 Cr
-57.01% YoY
25.99%
-8.6pp YoY
₹11.53
Natco Pharma's consolidated Q1 FY27 (quarter ended 30 June 2026) revenue fell 44.7% YoY to ₹735.2 Cr (₹1,328.9 Cr in Q1 FY26) and consolidated PAT fell 57.0% YoY to ₹206.5 Cr (₹480.3 Cr), as the company lost the high-margin exclusivity window on generic Lenalidomide (Revlimid) that powered last year's base. Sequentially revenue was roughly flat (-0.5% QoQ vs ₹739.1 Cr) but PAT fell 23.2% QoQ from ₹269.0 Cr — though that Q4 base was itself inflated by a one-off ₹115 Cr deferred-tax credit (Section 115BAA re-measurement) booked in the March 2026 quarter, so the underlying QoQ profit trend is less negative than the headline suggests. Adjusting for the ₹84.3 Cr share of profit now consolidated from associate Adcock Ingram Holdings (South Africa) — which contributed nothing a year ago — core consolidated PAT fell closer to 74.6% YoY to ₹122.2 Cr, a materially steeper decline than the 57.0% reported number.
Q1 FY-2027 vs prior quarters
The compression sits squarely in the topline mix: operating margin (EBITDA/revenue) fell to 25.4% from 43.0% a year ago, and net margin to 26.0% from 34.5%, as the International Formulations segment — home to the US Lenalidomide franchise — dropped to ₹477.1 Cr from ₹1,120.9 Cr YoY per the company's segmental disclosure. This was partially offset by the base business: API revenue rose to ₹66.7 Cr from ₹52.6 Cr (+27%) and Domestic Formulations to ₹136.4 Cr from ₹107.0 Cr (+27%) YoY, matching management's framing that base-business growth partially cushioned the Lenalidomide decline. Standalone (parent-only) numbers show the divergence starkly — standalone PAT fell 83.9% YoY to ₹74.6 Cr (₹464.1 Cr) versus the consolidated 57.0% decline, with the gap explained by the newly consolidated Adcock associate income and other overseas subsidiary contributions absent from the standalone book.
The stock went into the print at ₹890.15, down 7.9% over the past month of trading.
Management provided guidance for FY27, expecting revenue between INR3,400-3,500 crores and PAT of INR700-750 crores, acknowledging a dip from the previous year due to the decline in Lenalidomide revenue. The company anticipates compounding earnings growth of 15%-25% annually from FY28 onwards, driven by a diversified p
— This quarter: met
This decline was pre-signalled: on the Q4 FY26 call, management guided FY27 revenue of ₹3,400-3,500 Cr and PAT of ₹700-750 Cr, explicitly flagging a dip from the Lenalidomide falloff and framing FY27 as a base year ahead of a targeted 15-25% earnings CAGR from FY28. Annualising Q1 (₹735.2 Cr revenue, ₹206.5 Cr PAT) implies roughly a ₹2,941 Cr revenue run-rate — trailing the low end of guidance — while the PAT run-rate of about ₹826 Cr tracks ahead of the guided range, aided by the Adcock associate income; on balance the quarter reads as broadly consistent with the outlook management already set, not a material beat or miss. No independent brokerage consensus figure specific to the Q1 FY27 print was found in public searches; media reports note the stock had already corrected sharply in the days before results as the market pre-priced the exclusivity loss, so the street comparison is unknown rather than a clean beat or miss. On corporate actions, the board — at the same meeting — declared a ₹1.50/share interim dividend and approved evaluating a ₹2,000 Cr fundraise (equity/QIP/rights or combination), alongside board committee reconstitutions; NATCO also raised its Adcock Ingram stake to 49% in July 2026 (from 35.75%), the source of the associate income noted above.
W1
Base-business momentum: API (+27% YoY) and Domestic Formulations (+27% YoY) this quarter — whether this pace continues to offset the Lenalidomide roll-off through FY27
W2
Progress on the ₹2,000 Cr fundraise approval flagged 14-Aug-2026 — structure (equity/QIP/rights) and use of proceeds as approvals are sought
W3
FY27 guidance checkpoint: ₹3,400-3,500 Cr revenue / ₹700-750 Cr PAT guided; Q1 revenue run-rate (~₹2,941 Cr annualised) trails the low end while PAT run-rate (~₹826 Cr) is ahead — watch for convergence in H2
Lenalidomide cliff cuts deep; Brazil offsets but trajectory troubled
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Maintained FY27 guidance (3,400-3,500 Cr revenue, 700-750 Cr PAT) despite Q1 revenue miss, signaling confidence or miscalibration; requires 20%+ ramp in next 3 quarters to deliver.
Neutral
next 1–2 quarters
Optimistic
multi-year
Q1 revenue collapse (45% YoY) driven by expected Lenalidomide cliff, but shortfall on FY27 guidance trajectory is material: need 2,665 Cr in Q2-Q4 to hit 3,400 Cr target vs Q1's 735 Cr run rate. PAT guidance 700-750 Cr appears achievable on normalized basis (ex Adcock flu bump), but semaglutide margin pressure and olaparib litigation add risk.
₹794.4 Cr
Revenue · −44.7% YoY₹206.5 Cr
Reported PAT · −57% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Lenalidomide revenue lower, offset by base business double-digit growth
METRevlimid now negligible. Domestic base grew 107→130 Cr (+21.5%); semaglutide ~2 Cr/month, highly competitive, barely profitable
Strong growth in Brazil, 180% YoY
METBrazil revenue 178 Cr, confirmed 180% YoY growth, driven by oncology pipeline
EBITDA margin improved QoQ at 30.9%
METEBITDA 245.7 Cr, margin 30.9%; improvement attributed to international and domestic performance plus lower operating costs
PAT grew 34% QoQ (normalized basis)
METReported PAT 206.5 Cr vs Q4 269 Cr (Q4 included 115 Cr one-time tax benefit); normalized Q4 ~154 Cr, so growth ~34% checks out
Adcock contribution healthy, one-time flu season bump
METAdcock PAT 242.2 Cr; NATCO's 35.75% stake = 84.3 Cr (40% of total PAT). CFO acknowledged this quarter was abnormal; baseline ~35-40 Cr/quarter
Earnings quality
What changed since the last call
Lenalidomide revenue cliff realized
DowngradeRevlimid now negligible (was multi-hundred-crore contributor in FY26); explicit acknowledgment this is structural not temporary
FY27 revenue guidance maintained at 3,400-3,500 Cr
NeutralNot raised/cut despite Q1 at 735 Cr annualized (2,940 Cr); implies 20%+ Q2-Q4 average growth needed or guidance at risk of miss
Adcock stake increased to 49%
UpgradeINR1,060 Cr additional acquisition in July 2026; strategic deepening, now ~40% of NATCO's consolidated earnings (but volatile flu-season-driven)
Brazil becomes material growth engine
Upgrade180% YoY growth to 178 Cr; oncology pipeline driving, multiple launches planned for '27; positioned as 3-geography growth (Brazil, Canada, US)
Semaglutide India competitive intensity acknowledged
Downgrade~₹2 Cr/month revenue, market 'cutthroat', pricing pressure intense, expects 'settling down' but timeline vague and profitability distant
Fundraise planned, 2,000 Cr target
NewPost-Adcock spend (3,000 Cr in last year), company raised to fuel next wave of M&A and capex; larger opportunity 'outside India' hinted at
The Q&A
Analysts pressed on revenue miss and product-level details; management acknowledged Lenalidomide cliff but pivoted to base business growth and Brazil momentum. CEO somewhat evasive on M&A opportunities (declined specifics) and notably could not recall olaparib trial date. Light pushback on semaglutide profitability and Adcock earnings sustainability (flu-season bump). Overall tone: management defensive on near-term but bullish on medium-term pipeline, holding firm on guidance.
Geographic revenue breakdown — Vamsi, ASK IM
PartialBrazil 180% growth to 178 Cr; Canada 56 Cr. QoQ decline 14% attributed to seasonal cycles and Adcock flu season bump.
Domestic sales growth — Vamsi, ASK IM
AnsweredBase business 107→130 Cr (+21.5%); semaglutide significant contributor with third-party orders; domestic expected +25% volume growth FY27.
M&A opportunities — Vamsi, ASK IM
DodgedWill come back to you. (Deflection; no specifics provided)
Operating expense decline — Kunal Randeria, Axis Capital
AnsweredLast year Q1 had high R&D spend and legal costs (timing-dependent); current quarter lower, will fluctuate based on project milestones and batch spending.
International formulations QoQ decline — Kunal Randeria, Axis Capital
PartialDifferent product cycles, seasonal tendencies; don't provide product-by-product guidance; focus on larger picture and annual trajectory.
Export subsidiary revenue split — Rashmi Shetty, Dolat Capital
DodgedDon't have the split; smaller ones not available; will pass on this.
Crop Health profitability status — Rashmi Shetty, Dolat Capital
AnsweredQ1 loss due to El Niño delays and rain postponements; goal is FY27 breakeven; Q2 should be significantly better (strongest quarter for agro).
Revlimid contribution — Abhigyan Srivastav, Marcellus Investment Managers
AnsweredVery, very small. Negligible to say the least.
Tax rate guidance — Abhigyan Srivastav, Marcellus Investment Managers
AnsweredIndia new regime ~25.16% (plus CSR disallowances, ~27%). Global depends on geography mix. Brazil >35%, high this quarter. Difficult to guide precisely.
Carfilzomib launch status — Abhigyan Srivastav, Marcellus Investment Managers
PartialCannot confirm exact date due to confidentiality. On track; plant upgrade by year-end; will launch when date is set.
Olaparib litigation status — Abhigyan Srivastav, Marcellus Investment Managers
DodgedDon't remember the trial date, top of my head not able to recollect. Trial is scheduled next few months. Exclusivity determination pending.
South Africa growth strategy — Tanya Chaudhary, Investec
AnsweredSynergies: (1) NATCO pipeline for Adcock distribution, (2) Indian partner relationships, (3) R&D synergies. Value comes 2-3 years out; now stabilizing base earnings.
Brazil launches — Tanya Chaudhary, Investec
PartialOncology pipeline is driving growth. Other meaningful launches in '27 subject to patent litigation. Cannot name molecules (competitive).
Semaglutide sales estimate — Tanya Chaudhary, Investec
AnsweredBrand ~₹2 Cr/month. Lot of third-party business won't repeat. Market is cutthroat; pricing stability expected next few months.
Semaglutide profitability — Tanya Chaudhary, Investec
AnsweredDoesn't lose money, but doesn't make much money either.
South Africa trade deal impact — Arjun, Individual Investor
DodgedNot well informed, don't want to answer that question.
Semaglutide South Africa approval — Arjun, Individual Investor
PartialSun Pharma got approval. NATCO is a little away. Exploring third-party options. Dossier not yet filed. Don't have market size data.
Crop Health demerger timeline — Arjun, Individual Investor
AnsweredDemerger plans still active. Delayed 2-3 months due to fundraising activity. Probably March instead of December.
Fundraise rationale and cash — Pranav Chawla, JM AMC
AnsweredNet cash now ₹1,400 Cr. INR3,000 Cr spent on Adcock stakes over last year. Looking at acquisition opportunities, short-term loans, capex. Funds needed for M&A and readiness.
Capex requirements — Pranav Chawla, JM AMC
AnsweredRun rate ₹250-300 Cr annually for organic capex.
NATCO products in Adcock — Pranav Chawla, JM AMC
AnsweredFiled 3 dossiers. Registration takes 18-24 months. Estimate NATCO products to market around '28.
eGenesis innovation asset — Hrishikesh Patole, 360 ONE Capital Markets
PartialeGenesis doing reasonably well; transplants performed on multiple patients; 2 patients survived >8 months on pig kidney. Most valuable asset. Will have updates in next few months.
R&D pipeline and FTF targets — Hrishikesh Patole, 360 ONE Capital Markets
AnsweredInternal target 8-10 ANDAs/year; FTF target 2-3/year. Hoping to deliver 1-2 FTFs this year over pipeline already in hand.
FY27 PAT guidance reaffirm — Vamsi, ASK IM
AnsweredDon't annualize. Flu season bump. Guidance remains ₹750 Cr. Not changing guidance. Normally Adcock ~₹100 Cr/quarter, 49% see-through ≈₹49 Cr normalized.
Adcock stake increase strategy — Santosh, Individual Investor
AnsweredYes, committed to long-term South Africa strategy. Currently at 49%, Bidvest holds 51%, no opportunity now. Have first right of refusal. Will pursue if opportunity arises.
Land monetization potential — Arjun, Individual Investor
Answered15-20% of land tied in litigation (frivolous claims). Can sell at right price/time. Need all parcels clean or break into smaller pieces. Exploring but on hold.
Fundraise method (QIP vs rights) — Arjun, Individual Investor
PartialExploring all options: QIP, rights, others. Board allowed us to consider all. Will decide based on what's right. Considering rights as well.
R&D payback philosophy — Sahil Mahajan, Individual Investor
AnsweredDifferent payoffs. 8-9 year assets yield 20-40x. 12-month assets yield 15-20%. Longer wait = higher returns + higher risk. Think in 8-10 year cycles not 2-3 years.
R&D allocation long-term vs short-term — Sahil Mahajan, Individual Investor
Answered70-80% of money for things happening 2029 and beyond (range '28-'35); early payoffs are 15-20% return.
Adcock investment total rationale — Aman, Individual Investor
AnsweredClarified: Total 13.25% tranche was ₹1,060 Cr (not ₹1,400 Cr total). Strategic long-term investment in South Africa.
Controlling stake in Adcock pursuit — Aman, Individual Investor
AnsweredControlling stake not available; Bidvest holds 51%, not offering. Have first right of refusal. Will pursue if comes at right price. Currently 49% is the position.
Fundraise geography allocation — Aman, Individual Investor
PartialSmaller piece in India; large opportunity outside India. Evaluating various options. Not geography-specific but 2 opportunities identified.
Semaglutide filing status abroad — Hrishikesh Patole, 360 ONE Capital Markets
AnsweredNot filing in either. Status is minus. Dossier not being filed.
US market launches FY27-'29 — Hrishikesh Patole, 360 ONE Capital Markets
PartialIntend to launch with exclusivity. Can't name due to confidentiality. Have 2 launches in next financial year.
Crop Health CTPR exports — Hrishikesh Patole, 360 ONE Capital Markets
AnsweredSome level of exports done but not significant. Predominantly domestic focus. Working on registrations across geographies.
Crop Health portfolio launches — Hrishikesh Patole, 360 ONE Capital Markets
Answered35 products total; insecticides, fungicides. CTPR 8 products (30-35% revenue), rest non-CTPR (65-70%). Glanz brand (fungicide, limited competition) doing well. Pursuing 9(3) registrations (limited competition) for next year.
Guidance
FY27: ₹3,400-3,500 Cr (vs Q1 FY27 at 735 Cr)
MediumRequires ₹2,665 Cr in Q2-Q4 (avg 889 Cr/quarter); annualized Q1 would be 2,940 Cr, leaving ~400-500 Cr shortfall if no ramp. Likely requires strong Brazil and base business momentum.
Operating margin 25.4%, sustained on international and domestic growth mix
MediumEBITDA 30.9% this quarter suggests room; but semaglutide competition and Crop Health losses pressure near-term
Organic capex ₹250-300 Cr annually
HighRun-rate established; carfilzomib plant upgrade by year-end; modest ongoing maintenance
Risks the call surfaced
Revenue cliff risk
HighLenalidomide now negligible; was multi-hundred-crore legacy revenue driver. Q1 revenue 735 Cr (down 45% YoY) shows gap too large to fill quickly. FY27 guidance 3,400-3,500 Cr would require 20%+ Q2-Q4 average ramp.
Adcock earnings dependency and volatility
HighAdcock contributed 84.3 Cr PAT this quarter (40% of 206.5 Cr total). CFO acknowledged flu season bump; baseline is ₹35-40 Cr/quarter. If Adcock normalizes next quarter, consolidated PAT will drop sharply and create annualized FY27 miss risk (700-750 Cr guidance assumes 156-187 Cr/quarter from Adcock alone at 49% stake).
Pipeline execution and litigation risk
HighCarfilzomib launch confidential, plant upgrade required by year-end (schedule risk). Olaparib patent litigation trial scheduled 'next few months' but CEO couldn't recall exact date (concerning governance gap). 8-10 ANDA target with 2-3 FTF/year ambitious. Failure to deliver launches on timeline would hurt FY28+ growth assumptions.
Semaglutide market saturation and profitability gap
MediumSemaglutide India brand revenue ~₹2 Cr/month (24 Cr annualized). Market described as 'cutthroat'. CEO acknowledged 'doesn't lose money, but doesn't make much money either'. Not filed in Canada or Brazil (major geographies). Low profitability means limited upside despite hype; market 'settling down' over 'next few months' is vague.
Crop Health losses and demerger execution
MediumCrop Health Sciences Q1 revenue 40 Cr with EBITDA loss; management expects FY27 breakeven and Q2 strong recovery (strongest agro quarter). However, El Niño fear and rain delays caused Q1 weakness; external weather dependency creates execution risk. Demerger delayed 2-3 months (now targeted March vs December) due to fundraising, suggesting distraction/prioritization risk.
Management
Score 6/10. Mixed. Provided numbers on key segments (Brazil, Canada, domestic base) and maintained guidance firmly, but evasive on competitive details (M&A, product names, competitive markets). CEO notably couldn't recall olaparib trial date, suggesting gaps in depth of preparation. Challenged near-term. Lenalidomide cliff materialized as expected; missed on Q1 revenue guidance trajectory (annualized 2,940 Cr vs 3,400+ target), but PAT on track post-Adcock. Brazil 180% growth and domestic 21.5% growth show base business recovery mechanics working; however, semaglutide profitability and Crop Health losses are headwinds.
1 · FY27 (ongoing)
Domestic formulations ramp on semaglutide and base business; need sustained 850+ Cr/quarter to hit 3,400 Cr annual target
2 · CY 2027 (Calendar)
Carfilzomib launch (confidential date) post-plant upgrade completion; significant oncology revenue opportunity
3 · FY28 (est. 2028)
NATCO products registration in Adcock South Africa; 3 dossiers filed, typical 18-24 month registration cycle
PAT guidance 700-750 Cr appears achievable on normalized basis (ex Adcock flu bump), but semaglutide margin pressure and olaparib litigation add risk.
NATCO Pharma Q1 FY27: The Trough Year Begins—Revlimid Cliff and Specialty Ramp
NATCO faces Q1 FY27 as a structural reset year, driven by the Revlimid cliff—loss of generic exclusivity triggered a 39.5% revenue collapse in Q4 FY26. Management has guided FY27 revenue of ₹3,400–3,500 Cr (down 21% YoY) and called it a "trough year" before FY28 recovery. Q1 sits at the low end of this new normal. The real watch: whether new specialty launches (FDA-approved Olaparib, Eribulin) and the Adcock Ingram expansion provide enough catalyst for margin recovery.
The Setup: NATCO enters Q1 FY27 post-Revlimid cliff. The first half of FY26 (Q1–Q2) delivered a compelling ₹1,190–₹1,265 Cr run rate with operating margins at 44–45%, fueled by high-margin generic Revlimid exclusivity. Loss of exclusivity in late FY26 triggered a 39.5% YoY revenue collapse in Q4—Q3 fell to ₹529 Cr, Q4 to ₹609 Cr. Management has guided FY27 revenue of ₹3,400–3,500 Cr (21% decline from FY26 ₹4,300 Cr) and positioned FY27 as a "trough year" before FY28 recovery. The question for Thursday's result: does Q1 track the recent H2 norm (₹550–650 Cr) or slip further, and do margins stabilize toward 22–25% NPM as the worst of the Revlimid transition clears? Management's full-year guide implies an average quarterly run of ₹850–875 Cr; a Q1 significantly below that would flag execution risk.
On-Plan Expectations
~₹550–650 Cr
Anchored to H2 FY26 run rate (₹529–609 Cr); tracking recent quarterly average
~20–25%
Post-H2 compression recovery; Q4 stood at 30.8%, Q3 at 18.3%
~₹11–₹15
Reflecting mid-range revenue expectation; Q4 FY26 was ₹11.70
~18–23%
H2 compression persists unless manufacturing or mix normalizes
A strong print would show revenue tracking the upper end of the ₹550–650 Cr range (closer to ₹630 Cr) with operating margins stabilizing above 22%, suggesting the H2 slowdown was a temporary event (e.g., a delayed shipment, a one-time contract, or inventory build). A weak print would see revenue slip below ₹550 Cr or margins stay compressed below 18%, signaling structural headwinds in the generics or specialty portfolio that weren't baked into H2 guidance.
On-Track Assessment
Management has guided FY27 revenue of ₹3,400–3,500 Cr and PAT of ₹700–750 Cr, representing a 21% revenue decline and ~45% profit decline from FY26. Explicitly, management termed FY27 a "trough year" with recovery expected in FY28 as specialty launches (Semaglutide, Olaparib, Eribulin) and Adcock Ingram contributions scale. This implies an average quarterly run of ₹850–875 Cr for FY27. Q1 FY27 at ₹550–650 Cr (anchored to H2 FY26 actual) would signal Q1 is tracking weaker than the annual average, suggesting more severe H1 impact before H2 recovery. Key to watch on the call: confirmation of the ₹3,400–3,500 Cr guide, quarterly phasing (H1 vs H2 split), and PAT bridge—whether the ₹700–750 Cr reflects further margin compression or stabilization.
What the Street is Watching
Since Last Quarter: The Scorecard
Jun 3, 2026
FDA Approval: Eribulin Mesylate Injection (with Lupin)
Positive catalyst for US generics; launches later in FY27. Not in Q1 revenue.
Jun 30, 2026
VP Operations Superannuation (Nadella Malleswara Rao)
Routine succession; management continuity risk low.
Jul 6, 2026
R&D Designations: SVP Analytical R&D; VP Formulation
Management reinforcement in capability areas. Neutral to positive on innovation credibility.
Jul 8, 2026
Board Approves ₹1,400 Cr Investment in Natco Pharma South Africa (Adcock Ingram stake increase)
Strategic but capex-heavy; boosts long-term SA exposure (49% stake). Margin pressure in medium term; upside for FY27–28.
Jul 14, 2026
Adcock Ingram Stake Increased to 49% (~₹575 Cr transaction)
Completed. Unlocks synergies in African pharma but requires integration capex.
Jul 14, 2026
Tax Demand Notice from Andhra Pradesh (₹21.3 L + ₹17.2 L interest + ₹21.3 L penalty)
Regulatory overhang (~₹60 L aggregate). Likely appeal; immaterial to FY27 P&L but risk item.
May 15–May 29, 2026
NPPA Demand Notice: ₹4.92 Cr for Alleged Overcharging (Apr–Nov 2023)
Regulatory headwind; likely appeal. Does not affect Q1 FY27 reported profit but signals compliance scrutiny.
Jul 18, 2026
FDA Tentative Approval: Olaparib Tablets (100 mg, 150 mg) — AstraZeneca Lynparza® bioequivalent
Strong upside catalyst; launch in US market likely in FY27–28. Sets up significant grossed-up margin potential in specialty oncology.
Summary: The quarter shows mixed signals. FDA wins (Olaparib, Eribulin) are genuine upside drivers for H2 FY27 onwards, but Q1 itself will not benefit from their launch revenue. The Adcock Ingram stake increase is strategically sound for long-term African exposure but creates near-term capex drag and integration costs, unlikely to lift Q1 margins. Regulatory demands (NPPA, AP tax) add noise but appear manageable on appeal. The critical narrative is whether core generics revenue is stabilizing or declining—a theme that will unfold over the next four quarters.
What to Watch on Result Day
1 · Q1 Revenue vs. FY27 Guide
Does Q1 land ~₹825–875 Cr (tracking management's ₹3,400–3,500 Cr FY27 guide on average) or show Q1 weakness <₹750 Cr? The full-year guide is a floor expectation; phasing matters. If Q1 is materially below the quarterly average, it signals a front-loaded trough with H2 recovery required (a binary bet). Confirmation or reset of the guide is critical—any downgrade flags deeper Revlimid aftereffects or delay in new product ramps.
2 · Operating Margin Recovery
Can OPM climb back to 22–24% from H2's 15–23%? Margin drivers: input costs, capacity utilization, specialty mix, and manufacturing productivity. If OPM stays below 18%, expect Street repricing downward.
3 · Geographic Mix (US vs Domestic)
US generics are NATCO's profit engine but face intensity. Domestic pricing & volume trends matter equally. Any commentary on US ternary care wins or domestic formulations market share shifts will inform FY27 trajectory.
4 · Adcock Ingram Synergies & Capex Plans
Management should clarify capex pace for South Africa integration, expected synergy timelines, and any near-term margin headwinds. Investors want clarity on when African exposure becomes accretive.
5 · FDA Pipeline & Launch Timeline
Olaparib and Eribulin launch windows (Q2–Q3 FY27 estimate). Any commentary on other ANDA approvals or specialty oncology pipeline depth. This is the bull case for H2 FY27 forward.
6 · Regulatory Developments & Contingencies
Update on NPPA demand notice and Andhra Pradesh tax demand—legal status, provisioning, and confidence in appeal success. Regulatory clarity reduces execution risk.
NATCO Pharma has become a binary bet on the post-Revlimid turnaround. Management has framed FY27 as a "trough year"—a deliberate trough, not a surprise—with recovery seeded in FY28 as Semaglutide, Olaparib, and Eribulin scale. The ₹3,400–3,500 Cr FY27 guide represents a 21% decline from FY26, the steepest in recent memory. Q1 results will tell whether the guide is credible or conservative. If Q1 lands near ₹850 Cr and margins stabilize above 22% NPM, the market may front-run the FY28 recovery narrative—especially with FDA wins now in hand. Conversely, if Q1 slips below ₹700 Cr or margins stay sub-18%, the Street will push the turnaround timeline further out and likely re-rate downward. FII holding at 17.4% despite the 25% drawdown from ATH suggests some patience, but it's not a vote of confidence yet.
Three watch points drive the result on Thursday: (1) Q1 revenue phasing—is it tracking the annual guide or showing deeper weakness, and what's the H1 vs H2 split? (2) Margin stability—does NPM climb back to 20–25% as Revlimid washes out and mix normalizes? (3) Management tone on FY27 guide confidence, Adcock Ingram capex timeline, and new product launch sequencing. The stock's technical weakness (below all SMAs, RSI 36.4) mirrors Street caution. A credible execution narrative—confirmed guidance plus colour on H2 recovery—could spark a relief rally. Without it, expect consolidation range-bound at current depressed multiples.